Press release
Worldwide infectious disease treatments market is expected to grow at an approximate CAGR of 7.1% till 2023
The global infectious disease treatment market is growing mainly due to the rising prevalence of infectious diseases. According to a recent study report published by the Market Research Future, The global infectious disease treatment market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
Pathogenic microorganisms, such as bacteria, parasites, viruses or fungi, are the prime cause of infectious diseases. These diseases can also spread indirectly, from one person to another. Most of the infectious diseases consist of minor complications but some other infections such as, AIDS, pneumonia, and meningitis can become life-threatening. According to a study published in the American Journal of Epidemiology and Infectious Disease in 2017, it is observed that a high prevalence of intestinal infection was observed in people living with HIV/AIDS in Cameroon. The major predisposing factors behind this infection includes primary level of education, wells as source of drinking water, ownership of cats as pets, and having a blue collar job.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1626 .
Notably, increasing research and development expenditure is the key factor driving the infectious disease treatment market. In recent years various companies have introduced various innovative drugs for infectious diseases in the market. For instance, FDA has approved various drugs for Hepatitis B and C treatments such as Baraclude by Bristol-Myers Squibb, Epivir HBV by GlaxoSmithKline, Pegasys by Roche, Harvoni by Gilead, Incivek by Vertex Pharmaceuticals, Mavyret by AbbieVie, and others
Other factors such as, rising prevalence of various infectious diseases, huge research funding for research, and treatment, and rising approval from regulatory bodies are also fuelling the market growth.
Despite these drivers, stringent reimbursement policies, and presence of other fake drugs are expected to decline the market growth.
Global Infectious Disease Treatment Market - Competitive Analysis
The global infectious disease treatment market is currently dominated by few players.
GlaxoSmithKline is one of them by holding a strong share in the market. GSK plc. is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, the company has developed some of the leading global medicines in these fields. On Nov 22, 2017, Johnson & Johnson, and GlaxoSmithKline received FDA approval for an innovative combination of two drugs i.e. Tivicay/rilpivirine and Edurant/dolutegravir, to treat HIV infection.
Merck & Co., Inc. is also one of the leading player in infectious disease treatment market. The company’s stronghold is largely attributed to its innovative and sustainable products. On May 30, 2017, Merck received FDA approval for ISENTRESS® HD used for the treatment of HIV infection in adults, and pediatric patients. On September 06, 2017, Merck & Co., Inc. teamed up with Rigontec to expand its Immuno-Oncology segment.
AbbVie Inc. is another renowned market player in infectious disease treatment market. On August 3, 2017, AbbVie received approval for its Hepatitis C treatment drug, named as Mavyret (glecaprevir and pibrentasvir).
On October 14, 2015, Roche Molecular Systems, Inc. received FDA approval for cobas® HCV laboratory test for the detection of hepatitis C virus (HCV).
Novartis AG (Switzerland), Gilead (U.S.), Janssen Pharmaceutical, Inc. (Belgium), F. Hoffmann-La Roche Ltd. (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc (U.K), BioCryst Pharmaceuticals (U.S.), Merck & Co., Inc. (U.S.), and Boehringer Ingelheim GbH (Germany) are some of the prominent players at the forefront of competition in the infectious disease treatment market and are profiled in MRFR Analysis.
Browse Complete report at https://www.marketresearchfuture.com/reports/infectious-disease-treatments-market-1626 .
Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China which have a growing healthcare industry. Additionally, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax in India boosts the regional market growth.
On the other hand, the Middle East & Africa holds the least share in the global infectious disease treatments market due to the presence of poor economies in the African region. Moreover, the low per capita income and stringent government policies restrain the market growth within the African region. A majority of the market in the Middle East & Africa is held by the Middle East due to huge healthcare expenditures and presence of developed economies like Kuwait, Saudi Arabia, Dubai, and Qatar.
About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Worldwide infectious disease treatments market is expected to grow at an approximate CAGR of 7.1% till 2023 here
News-ID: 966474 • Views: …
More Releases from Market Research Future
Ophthalmic Topical Therapeutics Market | Global Market Analysis Report - 2035
Ophthalmic Topical Therapeutics: Advancing Eye Care Through Targeted Treatment
Ophthalmic topical therapeutics have become a cornerstone in modern eye care, offering precise, localized treatment for a wide range of ocular conditions. Unlike systemic medications, which circulate throughout the body and may produce unintended side effects, topical therapies deliver active compounds directly to the eye, ensuring higher efficacy and a faster onset of action. This localized approach not only improves treatment outcomes…
Mental Health Apps Market Share, Size, Growth and Forecast to 2035
Mental Health Apps: Transforming the Way We Care for Our Minds
In recent years, mental health has gained increasing recognition as an essential component of overall well-being. Despite growing awareness, many individuals still face barriers to accessing mental health support, including stigma, cost, and geographic limitations. Mental health apps have emerged as a transformative solution, leveraging technology to provide accessible, personalized, and convenient mental health care for millions worldwide.
The Rise of…
Surgical Gloves Market Size, Share, Growth | CAGR of 4.95%
Surgical Gloves: A Critical Component of Modern Healthcare
Surgical gloves have become an indispensable element in modern healthcare, serving as a first line of defense against contamination, infection, and disease transmission. These gloves are not just protective gear-they are a symbol of safety, hygiene, and precision in medical practice. Their significance spans from routine hospital procedures to complex surgical interventions, highlighting their essential role in patient care and medical safety protocols.
The…
Asia Pacific CRO Market Size, Share & Growth Report by 2035
Asia Pacific CRO Market: Driving Innovation and Transformation in the Clinical Research Landscape
The Asia Pacific Contract Research Organization (CRO) market has been witnessing significant growth over the past decade, emerging as a pivotal hub for clinical research and drug development. With a growing population, increasing prevalence of chronic diseases, and rising investments in healthcare infrastructure, the region has become an attractive destination for pharmaceutical and biotechnology companies seeking cost-effective and…
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
